Accumulating studies indicate that PRMT5 might be a potential therapeutic target in HCC, but the limitation of in vivo studies is the usage of HCC cell lines or xenograft models by passing over the efficacy in the remedy of spontaneous HCC [6]. This evidence concerns the gene PRMT5 and hepatocellular carcinoma.